Leading companies that provide contract research services for the pharmaceutical and biotechnology industries have contributed more than $670,000 to help aid victims of the September 11 terrorist attacks and their families.
Novartis to use ParXware to manage Phase III trial
PAREXEL reported today that in connection with the Company’s intercompany reconciliation process for the fiscal quarter ended September 30, 2000, the Company identified certain items that will require the Company to restate its consolidated balance sheet for the fiscal year ended June 30, 2000.
PAREXEL International Corporation, (Nasdaq: PRXL) one of the world’s largest contract biopharmaceutical outsourcing companies, today announced the appointment of Karel J. de Neef, M.D., Ph.D. as Principal Consultant, Regulatory Affairs Europe North Region.
Operating income continues to improve on 15% growth in revenue; Company beats consensus expectations by one cent
Collaboration to Enhance and Accelerate Drug Development in Japan
Providing services to support the clinical studies being conducted throughout Central and Eastern Europe.
Imaging expertise to assess clinical efficacy and safety strengthened with key appointment.
PAREXEL International Corporation, (Nasdaq: PRXL) one of the world’s largest biopharmaceutical outsourcing companies, today announced the addition of a new scientific leader to Worldwide Regulatory Affairs and North American Medical Services.
PAREXEL International Corporation (Nasdaq: PRXL) today announced the appointment of Susan Murphy Warren as Vice President, Corporate Marketing and Strategy.
PAREXEL International Corporation (Nasdaq: PRXL) today announced the addition of two new scientific leaders to the North American Medical Services (NAMS) Division.
PAREXEL International Corporation (Nasdaq: PRXL) today announced the appointment of Michael E. Woehler, Ph.D. as Senior Vice President, Clinical Research Services.
Quarterly gross margins improve year-over-year in all Strategic Business Units
PAREXEL International Corporation (Nasdaq: PRXL) today announced its acquisition of EDYABE, a leading Contract Research Organization in Latin America.
IT Subsidiary of PAREXEL Bundles Veritas Medicine’s Proprietary Clinical Trials Matching Technology With Its Web-based Offering for Pharmaceutical Industry
PAREXEL International Corporation (Nasdaq: PRXL) today announced that William U. Parfet was elected to its Board of Directors and has been appointed to serve on its Audit Committe
Companies Combine Clinical Development and Economic Analysis
PAREXEL International Corporation (Nasdaq: PRXL) today announced a collaborative agreement with MetaWorks, Inc. to offer evidence-based clinical information services to pharmaceutical, biotechnology and medical device clients.
Expert Safety Advisory Group to Assist in Post-Approval Safety Studies
PAREXEL International Corporation, (Nasdaq: PRXL) one of the world’s largest Contract Research Services Organizations, today announced the official opening of its newest U.S. site in Bedminster, New Jersey.
Perceptive Informatics, Inc. a division of PAREXEL International (Nasdaq: PRXL) announced today the appointment of Kurt J. Norris as Vice President and Chief Financial Officer.
Quarterly Revenue Hits Record High
PAREXEL International Corporation, (Nasdaq: PRXL) one of the world’s largest Contract Research and Medical Marketing Services Organizations, today announced the addition of three new scientific leaders to their North American Medical Services Division (NAMS).
PAREXEL International Corporation (Nasdaq: PRXL) announced today that Carl A. Spalding has been appointed President and Chief Operating Officer of the Company.
Barnett International, a division of PAREXEL International, LLC (Nasdaq: PRXL), announced today the expansion of its Consulting Management Team.
PAREXEL International Corporation (Nasdaq: PRXL) today announced that Michael J. McKelvey, Ph.D., has joined PAREXEL as Senior Vice President, Worldwide Data Management.
PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the second quarter ended December 31, 2000.
To meet the global need for quality clinical research translations, PAREXEL’s (Nasdaq: PRXL) Scientific and Medical Services Unit (SMS) now offers PAREXEL Translations.
